Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 27 | Rare Historical Photos

Drugmakers sued over insulin prices

California's Attorney General Rob Bonta sued the six major companies that dominate the U.S. insulin market

Salon

Eli Lilly, insulin makers sued by California over prices

Eli Lilly & Co., Novo Nordisk AS and Sanofi were sued by California over insulin prices, which the state claims are inflated through unfair and deceptive practices and disproportionately affect low-income households and people of color.

Tribune News Service

California latest to sue drug companies over insulin prices

California says it will sue the companies that make and promote much of the nation's insulin

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

New guidance: Use drugs, surgery early for obesity in kids

New guidelines suggest children struggling with obesity should be evaluated and treated early and aggressively

The Independent UK

Semaglutide is causing a social media frenzy. So what is it?

It is not a a viral meme, but a drug that is an injectable medication — originally designed to treat diabetes — that has left those who need it waiting until next year for resupply.

ABC News

The growing market for weight loss drugs

A new generation of FDA-approved diabetes drugs that can also help patients lose weight has prompted enthusiasm from doctors and a firestorm of demand among patients so strong it's led to shortages.

Axios

Can diabetes medications really help you lose weight like Elon musk claims?

Recently, the news of Tesla CEO Elon Musk's 13kg weight loss transformation took over the internet by storm. In a Twitter post, Musk credited fasting and a diabetes drug called Wegovy for his "fit, ripped and healthy" physique. Since then words like Ozempic and Wegovy, both of which are injectable…

The Times of India

Read news from The Economist, FT, and more,
with one subscription

Patients complain some obesity care startups offer pills, and not much else

Many Americans turn to the latest big idea to lose weight — fad diets, fitness crazes, dodgy herbs and pills, bariatric surgery, just to name a few. They’re rarely the magic solution people dream of.

Tribune News Service

Concerns rise over obesity care startups

Concerns emerge over a wave of new startups offering access to drugs called GLP-1 agonists

Salon

Weight loss drug causing chaos on TikTok

A diabetes drug is all the rage among Hollywood’s elite, but folks who need the drug are struggling to get it

Salon

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

The Independent UK

‘I miss eating’: the truth behind the weight loss drug that makes food repulsive

In Beverly Hills’ doctors offices, celebrities are clamoring for Ozempic prescriptions – but what are the costs of the supposed wonder drug?

The Guardian - US

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

3 Stocks No One Is Talking About but Should Be

Amid an uncertain market, it becomes increasingly difficult for investors to find stocks that can survive the challenges and deliver solid returns. Accel Entertainment (ACEL), Novo Nordisk (NVO), and Titan Machinery (TITN) are currently not on investors’ radar, but it could be worth adding these stocks to one’s portfolio given…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Financial Times

A new ‘miracle’ weight-loss drug really works — raising huge questions

Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

Benzinga

Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market capitalization of $251.98 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Upgrades

Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

Upgrades

The Guardian - AU

Shortage of diabetes medication Ozempic after TikTok users promote drug for weight loss

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

Benzinga

Peering Into Novo Nordisk's Recent Short Interest

Novo Nordisk's (NYSE:NVO) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 0.12% of all regular shares that are available for trading.

Benzinga

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 14.2%. Currently, Novo Nordisk has a market capitalization of $253.71 billion.

1 … 25 26 27 28

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.